In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report), with a price target of $16.00. The company’s shares opened today at $7.58.
Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, CareDx, and Kiora Pharmaceuticals. According to TipRanks, Chen has an average return of -14.4% and a 31.98% success rate on recommended stocks.
Currently, the analyst consensus on Sensus Healthcare is a Strong Buy with an average price target of $14.67, representing a 93.54% upside. In a report released today, Alliance Global Partners also maintained a Buy rating on the stock with a $14.50 price target.
See today’s best-performing stocks on TipRanks >>
Based on Sensus Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.01 million and a net profit of $1.83 million. In comparison, last year the company earned a revenue of $5.53 million and had a net profit of $195 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Read More on SRTS:
- Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
- Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023
- Sensus Healthcare announces senior managment appointments
- Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues
- Sensus sees Q4 revenue of over $13M, consensus $12.25M
